[{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Descartes 30","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Descartes-11","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"RNA Engineered Allogeneic Human Mesenchymal Stem Cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Cartesian Therapeutics"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.13,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-15","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Cartesian Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Cartesian Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-08 is a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Juvenile Dermatomyositis.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 09, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-15 is the next-generation autologous anti-BCMA mRNA-engineered mRNA CAR-T cell therapy. It is being investigated for Relapsed/Refractory Multiple Myeloma.

                          Brand Name : Descartes-15

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 03, 2024

                          Lead Product(s) : Descartes-15

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The Company intends to use the net proceeds from the financing to fund its pipeline, which includes Descartes-08, a potential first-in-class mRNA CAR-T for patients with generalized myasthenia gravis.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 02, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Leerink Partners

                          Deal Size : $130.0 million

                          Deal Type : Private Placement

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for SLE.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 02, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 02, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of MG.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 22, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-08 is a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). It is under phase 2 clinical development for generalized myasthenia gravis.

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          January 08, 2024

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of my...

                          Brand Name : Descartes-08

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 13, 2023

                          Lead Product(s) : Descartes-08

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Selecta Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory disease...

                          Brand Name : Descartes-30

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 04, 2021

                          Lead Product(s) : RNA Engineered Allogeneic Human Mesenchymal Stem Cells

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : National Institutes of Health

                          Deal Size : $2.0 million

                          Deal Type : Funding

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies.

                          Brand Name : Descartes-11

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 22, 2021

                          Lead Product(s) : Descartes-11

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank